Sanctuary Advisors LLC Buys 4,118 Shares of Icon Plc $ICLR

Sanctuary Advisors LLC raised its stake in shares of Icon Plc (NASDAQ:ICLR) by 83.5% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 9,050 shares of the medical research company’s stock after purchasing an additional 4,118 shares during the period. Sanctuary Advisors LLC’s holdings in Icon were worth $1,001,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also recently modified their holdings of the stock. Geneos Wealth Management Inc. lifted its position in Icon by 11.5% in the second quarter. Geneos Wealth Management Inc. now owns 541 shares of the medical research company’s stock worth $79,000 after buying an additional 56 shares during the last quarter. Signaturefd LLC raised its position in Icon by 12.6% in the 4th quarter. Signaturefd LLC now owns 643 shares of the medical research company’s stock worth $117,000 after purchasing an additional 72 shares during the period. New Wave Wealth Advisors LLC lifted its stake in Icon by 5.1% in the fourth quarter. New Wave Wealth Advisors LLC now owns 1,479 shares of the medical research company’s stock worth $270,000 after purchasing an additional 72 shares during the last quarter. Janney Montgomery Scott LLC lifted its stake in Icon by 0.4% in the fourth quarter. Janney Montgomery Scott LLC now owns 23,942 shares of the medical research company’s stock worth $4,363,000 after purchasing an additional 93 shares during the last quarter. Finally, 1900 Wealth Management LLC boosted its position in shares of Icon by 4.4% during the fourth quarter. 1900 Wealth Management LLC now owns 2,430 shares of the medical research company’s stock valued at $443,000 after buying an additional 103 shares during the period. Hedge funds and other institutional investors own 95.61% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on ICLR shares. Weiss Ratings downgraded Icon from a “sell (d+)” rating to a “sell (d)” rating in a report on Friday, May 29th. TD Cowen upped their price objective on Icon from $164.00 to $197.00 and gave the company a “buy” rating in a research report on Thursday, June 25th. Royal Bank Of Canada upgraded Icon from a “sector perform” rating to an “outperform” rating and lifted their target price for the stock from $126.00 to $185.00 in a research report on Thursday, June 25th. Robert W. Baird upped their price target on shares of Icon from $168.00 to $186.00 and gave the stock an “outperform” rating in a report on Thursday, June 25th. Finally, Citigroup lifted their price objective on shares of Icon from $140.00 to $165.00 and gave the company a “neutral” rating in a report on Thursday, June 25th. Seven equities research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and three have given a Sell rating to the stock. According to MarketBeat.com, Icon currently has an average rating of “Hold” and an average target price of $168.73.

Icon Price Performance

Shares of ICLR opened at $165.76 on Friday. The company has a 50 day moving average price of $151.11 and a 200-day moving average price of $136.43. Icon Plc has a fifty-two week low of $66.57 and a fifty-two week high of $203.91. The stock has a market capitalization of $12.69 billion, a PE ratio of 29.49, a PEG ratio of 8.14 and a beta of 1.22. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.14 and a current ratio of 1.14.

About Icon

Icon plc (NASDAQ: ICLR) is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas.

Icon’s service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions.